Literature DB >> 29452040

Progress in the Control of Chemotherapy-Induced Emesis: New Agents and New Studies.

Richard J Gralla, Harry Raftopoulos.   

Abstract

New agents and studies have demonstrated benefit in improving antiemetic therapy. Incorporating evidence-based guideline recommendations and appropriate emesis assessments are key components to achieving the best practice.

Entities:  

Year:  2009        PMID： 29452040      PMCID： PMC2790682          DOI： 10.1200/JOP.0938502

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


  15 in total

1.  Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects.

Authors:  Kenneth C Lasseter; Jay Gambale; Bo Jin; Art Bergman; Marvin Constanzer; James Dru; Tae H Han; Anup Majumdar; Judith K Evans; M Gail Murphy
Journal:  J Clin Pharmacol       Date:  2007-05-24       Impact factor: 3.126

2.  Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients.

Authors:  Walter J Loos; Ronald de Wit; Steven J Freedman; Kristien Van Dyck; Jay J Gambale; Susie Li; Gail M Murphy; Connie van Noort; Peter de Bruijn; Jaap Verweij
Journal:  Cancer Chemother Pharmacol       Date:  2006-10-19       Impact factor: 3.333

3.  The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.

Authors:  Paul J Hesketh; Steven M Grunberg; Richard J Gralla; David G Warr; Fausto Roila; Ronald de Wit; Sant P Chawla; Alexandra D Carides; Juliana Ianus; Mary E Elmer; Judith K Evans; Klaus Beck; Scott Reines; Kevin J Horgan
Journal:  J Clin Oncol       Date:  2003-10-14       Impact factor: 44.544

4.  Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.

Authors:  R Gralla; M Lichinitser; S Van Der Vegt; H Sleeboom; J Mezger; C Peschel; G Tonini; R Labianca; A Macciocchi; M Aapro
Journal:  Ann Oncol       Date:  2003-10       Impact factor: 32.976

5.  Incidence of chemotherapy-induced nausea and emesis after modern antiemetics.

Authors:  Steven M Grunberg; Robert R Deuson; Panagiotis Mavros; Olga Geling; Mogens Hansen; Giorgio Cruciani; Bruno Daniele; Gerard De Pouvourville; Edward B Rubenstein; Gedske Daugaard
Journal:  Cancer       Date:  2004-05-15       Impact factor: 6.860

6.  Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.

Authors:  Peter Eisenberg; Jazmin Figueroa-Vadillo; Rosalio Zamora; Veena Charu; Julio Hajdenberg; Alan Cartmell; Alberto Macciocchi; Steven Grunberg
Journal:  Cancer       Date:  2003-12-01       Impact factor: 6.860

7.  Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.

Authors:  Steven M Grunberg; Matthew Dugan; Hyman Muss; Marie Wood; Susan Burdette-Radoux; Tracey Weisberg; Marisa Siebel
Journal:  Support Care Cancer       Date:  2008-11-27       Impact factor: 3.603

Review 8.  Imaging substance P receptors (NK1) in the living human brain using positron emission tomography.

Authors:  Richard Hargreaves
Journal:  J Clin Psychiatry       Date:  2002       Impact factor: 4.384

9.  Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment.

Authors:  H J Schmoll; M S Aapro; S Poli-Bigelli; H-K Kim; K Park; K Jordan; J von Pawel; H Giezek; T Ahmed; C Y Chan
Journal:  Ann Oncol       Date:  2006-03-08       Impact factor: 32.976

10.  Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC antiemesis tool.

Authors:  Alexander Molassiotis; Peter A Coventry; Carrie T Stricker; Caroline Clements; Beth Eaby; Luke Velders; Cynthia Rittenberg; Richard J Gralla
Journal:  J Pain Symptom Manage       Date:  2007-05-23       Impact factor: 3.612
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.